Gary T. Shearman

Gary T. Shearman

Geen lopende functies

Health Technology
Finance
Consumer Services

Profiel

Gary T.
Shearman
formerly worked at Woodbrook Group Holdings, Inc., as President, Chief Executive Officer & Director, Nereus Pharmaceuticals, Inc., as Chairman, HBM Advisors USA LLC, as Chairman, Artisan Pharma, Inc., as Executive Chairman, Merck & Co., Inc., as Director-International Regulatory Affairs in 1992, ChemoCentryx, Inc., as Director, Bellus Health (Innodia), Inc., as Director, Rhone-Poulenc Rorer, Inc., as Senior Vice President-Global Drug Development in 2000, HBM Healthcare Investments AG, as Investment Manager, HBM Biocapital Ltd., as Investment Manager, and Max-Planck Institute of Psychiatry, as Fellow.
Dr. Shearman received his graduate degree and doctorate degree from the University of Rhode Island and undergraduate degree from the University of Massachusetts.

Eerdere bekende functies van Gary T. Shearman

BedrijvenFunctieEinde
Voorzitter 29-04-2013
WOODBROOK GROUP HOLDINGS INC. President 05-06-2008
Corporate Officer/Principal 01-01-2000
MERCK & CO., INC. Algemeen Adviseur 01-01-1992
Max-Planck Institute of Psychiatry Corporate Officer/Principal -
Ervaring van Gary T. Shearman in detail bekijken

Opleiding van Gary T. Shearman

University of Rhode Island Doctorate Degree
University of Massachusetts Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Gary T. Shearman in detail bekijken

Connecties

82

Eerstegraads connecties

13

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven2
MERCK & CO., INC.

Health Technology

WOODBROOK GROUP HOLDINGS INC.

Finance

Bedrijven in privébezit9

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Finance

Finance

Health Services

Max-Planck Institute of Psychiatry

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Gary T. Shearman
-40 % Uitzonderlijk verlengd: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU